Heterogeneity of anoikis in triple-negative breast cancer subtyping and therapeutic implications  

作　　者：Kun Fang Suxiao Jiang Zhengjie Xu Meng Luo Changsheng Yan 

机构地区：[1]Department of Surgery,Yinchuan Maternal and Child Health Hospital,Yinchuan,Ningxia 750001,China [2]Department of Surgery,The First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang 150081,China

出　　处：《Genes & Diseases》2025年第1期114-117,共4页基因与疾病(英文)

基　　金：supported by a Ningxia Reproductive Disease Clinical Medical Research Center Project(2023-LCYX003);Ningxia Hui Autonomous Region Natural Science Foundation Project(2022AAC03748);Ningxia Hui Autonomous Region Natural Science Foundation Project(2021AAC03523);Yinchuan Science and Technology Innovation Project(2023SF25);Basic research project of Yinchuan Maternal and Child Health Hospital(2022NYFYCX05);Basic research project of Yinchuan Maternal and Child Health Hospital(2023NYFYCX01).

摘　　要：Triple-negative breast cancer(TNBC)is an inherently heterogeneous malignancy at the biological and clinical levels,occupying around 15%of diagnosed breast cancer cases and being the most lethal breast cancer subtype to combat.1 Anoikis is a programmed cell death that occurs when cells detach from the correct extracellular matrix,thereby destroying integrin connections.2 However,the role of anoikis expression pattern and prognosis in TNBC is still unrevealed.Here,TNBC presented three heterogeneous phenotypes in anoikis,and each subtype owned unique molecular,and clinical characteristics as well as diverse responses to chemotherapy,targeted therapies,and immune checkpoint blockade.The anoikis-based scoring system can accurately estimate patient survival,which was remarkably superior to well-established clinical parameters.

关 键 词：BREAST cancer clinical 

分 类 号：R737.9[医药卫生—肿瘤]